{"entity":{"id":"nct06508931","kind":"trial","name":"Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms","aka":["DALY PED"],"tldr":"A phase 2 trial of Zamtocabtagene autoleucel in advanced solid tumours, run by Miltenyi Biomedicine GmbH, now recruiting.","summary":"Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms is a phase 2 interventional study registered as NCT06508931 by Miltenyi Biomedicine GmbH, with 31 participants planned, started 2025-08-04 and due to reach its primary completion in 2029-12-31. Interventions recorded: zamtocabtagene autoleucel (MB-CART2019.1).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06508931","url":"https://clinicaltrials.gov/study/NCT06508931"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["zamtocabtagene-autoleucel"],"companies":["miltenyi-biomedicine"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06508931","phase":"2","setting":"A Single-arm, Multi-center, Open-label Phase II Study to Determine the Safety and Efficacy of MB-CART2019.1 in Pediatric Subjects With Relapsed/Refractory Mature B-cell Neoplasms Who Have Relapsed After One or More Prior Therapies, Including Subjects With Primary Refractory Disease","sponsor":"Miltenyi Biomedicine GmbH","participation":[{"nct":"NCT06508931","source":"https://clinicaltrials.gov/study/NCT06508931","fetchedAt":"2026-10-07T16:54:45.035Z","studySha256":"f2a95b720886612e26cd8d18c695dce9b3d4445bccc709a157550eb47b64b92c","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-05","leadSponsor":"Miltenyi Biomedicine GmbH","collaboratorCount":1,"minimumAge":"6 Months","maximumAge":"17 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":31,"enrolmentType":"ESTIMATED","siteCount":5,"recruitingSiteCount":2,"countries":["France","Germany","Italy","Netherlands"]}],"started":"2025-08-04","startedType":"actual","enrolled":31,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06508931/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"zamtocabtagene-autoleucel","kind":"drug","name":"Zamtocabtagene autoleucel","route":"/drugs/zamtocabtagene-autoleucel/"}],"company":[{"id":"miltenyi-biomedicine","kind":"company","name":"Miltenyi Biomedicine","route":"/companies/miltenyi-biomedicine/"}]}}